VRTX (vrtx.com) Earnings per share growth this year

Under the leadership of Reshma Kewalramani, Vertex Pharmaceuticals (VRTX) masterfully monetizes exclusive developments, creating a powerful cash flow. The annual EPS range on this precise GURU.Markets chart demonstrates growth driven by production diversification and independence from macro cycles due to its monopoly in cystic fibrosis treatment. Meanwhile, the -1.40 mark indicates the current level of earnings per share dynamics.

VRTX (vrtx.com) Earnings per share growth in current year history from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for vrtx.com (VRTX)

- stock value and consensus price forecast:

Market Price Vertex Pharmaceuticals Inc.|VRTX - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Vertex Pharmaceuticals Incorporated|VRTX - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value of a Share Vertex Pharmaceuticals|VRTX - Company Book Value|Market Capitalization to Net Assets vrtx.com|VRTX - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

VRTX - Net Income|Expected Profit Vertex Pharmaceuticals|VRTX - P/E Multiple|Projected Price to Earnings Ratio vrtx.com|VRTX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Vertex Pharmaceuticals Incorporated|VRTX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Vertex Pharmaceuticals|VRTX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months vrtx.com|VRTX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Vertex Pharmaceuticals

- revenue and sales proceeds data:

VRTX - Company Sales|Company Future Revenue Vertex Corp|VRTX - Price-to-Revenue Ratio|Future Price to Revenue Vertex Pharmaceuticals

Basic company analysis:Vertex Corp (VRTX)

Manufactured products of Vertex Pharmaceuticals

A conservative fundamental analysis of Vertex Pharmaceuticals (VRTX) requires an assessment of net income sustainability through earnings per share dynamics. This relative EPS YoY trend measures the annual percentage deviation of earnings, confirming management's ability to convert its monopoly in cystic fibrosis therapies and advancements in genetic engineering into stable financial growth, which characterizes the company as a highly predictable asset.

Main competitors